| human | Q5 |
| P496 | ORCID iD | 0000-0002-8663-0067 |
| P108 | employer | Brigham and Women's Hospital | Q2900977 |
| P734 | family name | O'Donoghue | Q21453164 |
| O'Donoghue | Q21453164 | ||
| O'Donoghue | Q21453164 | ||
| P735 | given name | Michelle | Q15621047 |
| Michelle | Q15621047 | ||
| P106 | occupation | researcher | Q1650915 |
| Q92451898 | A catalog of genetic loci associated with kidney function from analyses of a million individuals |
| Q114092988 | A polygenic risk score predicts atrial fibrillation in cardiovascular disease |
| Q102055428 | Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients with Cardiometabolic Disease |
| Q38424365 | Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial |
| Q36973414 | Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial |
| Q30276497 | Exome Genotyping Identifies Pleiotropic Variants Associated with Red Blood Cell Traits |
| Q92527797 | Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure |
| Q30276495 | Large-Scale Exome-wide Association Analysis Identifies Loci for White Blood Cell Traits and Pleiotropy with Immune-Mediated Diseases |
| Q101155742 | Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline |
| Q37590925 | Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials |
| Q30276496 | Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals |
| Q38881638 | Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials |
| Q46868498 | Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc |
| Q47177885 | Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity |
| Q92503516 | Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity |
| Q51762287 | Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. |
| Q51779676 | Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. |
| Q114683113 | Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE) |
| Q57243395 | Study design and rationale for the Stabilization of pLaques usIng Darapladib—Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome |
| Q90727038 | The Effect of PCSK9 Inhibition on the Risk of Venous Thromboembolism |
| Q96581276 | The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y12 Inhibitor in Patients after Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis |
| Q43292405 | The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizi |
Search more.